Rubin Steven D 4

What Happened

• Steven D. Rubin, a director of Eloxx Pharmaceuticals (ELOX), received a derivative equity award of 179,854 restricted stock units (RSUs) on September 19, 2025 (reported as $0 value). On January 24, 2026, 1,875 RSUs/options were converted/exercised into common shares and the same 1,875 shares were reported disposed at $0 — the filing indicates a conversion and simultaneous surrender/withholding rather than an open‑market sale.

Key Details

• Grant: 179,854 RSUs granted on 2025-09-19; reported acquisition price $0 (derivative award). (Footnote F1: each RSU = right to one common share.)
• Conversion/Disposition: 1,875 shares converted/exercised and 1,875 shares disposed on 2026-01-24; disposition reported at $0 (derivative).
• Vesting/option notes: Footnote F2 describes an option vesting schedule (1/36 vested Oct 31, 2025, then monthly thereafter). Footnote F3 describes RSU vesting (50% on first anniversary of Jan 24, 2024, remainder in two equal annual installments).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timing: Form 4 filed on 2026-05-08 reporting transactions from 2025-09-19 and 2026-01-24 — this filing was submitted months after the transaction dates.

Context

• RSUs are contingent rights to receive shares; conversion/exercise (transaction code M) typically means the units vested and were converted into shares. The reported $0 disposition is commonly used when shares are surrendered or withheld to satisfy tax withholding or other obligations rather than sold for cash; the filing does not show an open‑market sale.
• These entries look routine for equity compensation and do not, by themselves, indicate a purchase or sale for investment exposure.